Real-world analysis of treatments, healthcare costs, and overall survival among patients with metastatic non-small cell lung cancer by molecular biomarker testing approach.

Julie A Wiedower¹, Karen M Stockl², Jamie Tucker³, Shaun P Forbes⁴, Nicole Zhang⁵, Keelia Clemens⁶, Julia M Certa⁷, Pamela Morin⁸, Lucy Langer⁹

¹Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA, 94063, USA. Electronic address: jkaylor@guardanthealth.com.

²Optum, Inc., 1 Optum Cir, Eden Prairie, MN, 55344, USA. Electronic address: karen.stockl@optum.com.

³Optum, Inc., 1 Optum Cir, Eden Prairie, MN, 55344, USA. Electronic address: jamie.m.tucker@optum.com.

⁴Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA, 94063, USA. Electronic address: sforbes@guardanthealth.com.

⁵Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA, 94063, USA. Electronic address: niczhang@guardanthealth.com.

⁶Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA, 94063, USA. Electronic address: kclemens@guardanthealth.com.

⁷Optum, Inc., 1 Optum Cir, Eden Prairie, MN, 55344, USA. Electronic address: julia.certa@optum.com.

⁸Optum, Inc., 1 Optum Cir, Eden Prairie, MN, 55344, USA. Electronic address: pamela.morin@optum.com.

⁹United HealthCare Services, Inc., 9700 Health Care Ln, Minnetonka, MN, 55343, USA. Electronic address: lucy.langer@uhc.com.

PubMed DOI

Abstract

PURPOSE: To evaluate biomarker-targeted therapy utilization, healthcare costs, and overall survival (OS) with comprehensive genomic profiling (CGP), small panel, or no molecular testing for patients with metastatic non-small cell lung cancer (mNSCLC). PATIENTS AND METHODS: This retrospective claims analysis identified patients with newly diagnosed mNSCLC (index date) from 08/01/2020-12/31/2022, u…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.